Early Detection, Diagnosis, and Treatment of ATTR (Enduring)

 

 


This enduring material  is open to all specialties.  The program focuses on the following key areas:

  • Early Recognition and Diagnosis: Identifying signs and symptoms of transthyretin amyloidosis (ATTR) and addressing barriers to timely diagnosis and patient management.
  • Multimodality Imaging: Exploring the role of cardiac MRI, echocardiography, and other imaging tools in diagnosing ATTR-CM.
  • Treatment Options: Reviewing FDA-approved therapies and discussing promising emerging treatments

Launched: June 15, 2026

Expires: June 15, 2027

Music by Sree Nand from Pixabay

Target Audience

This program is designed for a broad audience of clinicians involved in the care and treatment of patients with amyloidosis, including general cardiologists, neurologists, hematologists, heart failure specialists, primary care as well as nurses in these areas.

Learning Objectives

Following participation in this webinar, participants will be able to:

  1. Identify key clinical signs and red flags associated with ATTR that warrant further evaluation.
  2. Describe the recommended diagnostic pathways for confirming a diagnosis of ATTR, including the appropriate use of imaging, lab testing and genetic screening.
  3. Discuss current FDA-approved therapies for ATTR, including indications, mechanism of action and considerations for clinical use.
  4. Effectively make a timely diagnosis and initiate appropriate treatment for patients with ATTR
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 ANCC
    • 0.50 ANCC Pharmacology
  • 1.50 Participation
Course opens: 
06/15/2026
Course expires: 
06/14/2027
Rating: 
0

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 
 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

Ahmad Masri, MD

Cardiomyopathy Section Head
Director, Hypertrophic Cardiomyopathy Center and Cardiac Amyloidosis Program
Associate Professor of Medicine
Oregon Health & Science University
Dr. Mastri is a consultant for  Cytokinetics, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, and Neurimmune and has
received grant/research support from Pfizer, Attralus, Cytokinetics and Janssen.
 
Nitasha Sarswat, MD
Assistant Professor, Department of Cardiology
University of Chicago
Dr. Sarswat has received research funding from Pfizer and BridgeBio .
 
Omar Siddiqi, MD
Director of Cardiovascular Medicine Fellowship Program
Boston Medical Center
Clinical Associate Professor of Medicine
Cardiovascular Medicine
Boston University Chobanian & Avedisian School of Medicine
Dr. Siddiqi has no relevant financial relationships.
 
Jill Stratford Waldron, APRN, GNP-BC
University of Utah Advanced Heart Failure Program
Utah Amyloidosis Program Center of Excellence
Ms. Stratford Waldron is a consultant for Alnylam, Bridge Bio and AstraZeneca and is on the Alnylam and Bridge Bio speaker’s bureaus.
 
None of the faculty plan on discussing unlabeled/investigational uses of a commercial product.
 
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the Amyloidosis Research Consortium (ARC). Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Contact Hours: 1.50 of which 0.50 are eligible for pharmacology credit

Available Credit

  • 1.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 ANCC
    • 0.50 ANCC Pharmacology
  • 1.50 Participation

Support

This activity is provided by educational grants from :

Alnylam

AstraZeneca

Bridge Bio

Pfizer

Please login or register to take this course.